Headlines about Genetic Technologies (NASDAQ:GENE) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genetic Technologies earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.4580708245556 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Genetic Technologies (NASDAQ:GENE) traded up $0.01 during trading on Tuesday, hitting $0.80. 78,306 shares of the company traded hands, compared to its average volume of 249,076. Genetic Technologies has a 12 month low of $0.70 and a 12 month high of $2.89.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/07/genetic-technologies-gene-receives-daily-news-impact-score-of-0-09.html.

Genetic Technologies Company Profile

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

Insider Buying and Selling by Quarter for Genetic Technologies (NASDAQ:GENE)

Receive News & Stock Ratings for Genetic Technologies Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies Ltd and related stocks with our FREE daily email newsletter.